The broader range of lenvatinib’s anti-angiogenic inhibition via blockade of VEGFR1-3 may be more effective for the treatment of gastric cancer than selective VEGFR-2 inhibition that ramucirumab provides. The gene discussed is KDR; the disease is gastric cancer.